



# OxySure (OXYS) Selected by USPTO to Exhibit OxySure Model 615 and Related Technologies at Innovation Expo at Smithsonian

FRISCO, TEXAS, UNITED STATES, September 16, 2014 /EINPresswire.com/ -- OxySure(R) Systems, Inc. (OXYS: OTCQB) ("OxySure," or the "Company"), a medical device innovator of life-saving, easy-to-use emergency oxygen solutions with its "oxygen from powder" technology, is pleased to announce that



the Company has been selected by the United States Patent and Trademark Office (USPTO) to exhibit its OxySure Model 615 portable emergency oxygen system and other OxySure technologies at the USPTO's Innovation Expo to be held at The Smithsonian. The expo will be held from 10 a.m. EST to 5 p.m. EST on Saturday and Sunday, November 1-2, 2014 at the National Air and Space Museum at the National Mall in Washington, D.C.

The OxySure Model 615 is an FDA-approved breakthrough technology that is defining a new market with no direct competition. Protected by a robust patent portfolio, the Company's Model 615 targets enormous end markets that are at least as large as the install base for automated external defibrillators (AEDs), which exceeds two million units in the US, and potentially as large as the fire extinguisher base, which exceeds 100 million units in the U.S. and more than 500 million units globally. The OxySure Model 615 is also CE Marking approved.

A revolutionary portable emergency oxygen system using OxySure's "oxygen from powder" technology, the Model 615 allows a parent, bystander, or victim to administer lifesaving oxygen in the event of a medical emergency, prior to the arrival of first responders. This safety net creates improved medical outcomes; thousands of saves have already been reported in emergencies involving cardiac arrest (used post-resuscitation), heart attacks, stroke, asthma attacks (in conjunction with a bronchodilator, as applicable), COPD exacerbations, heat exhaustion, hypoxia/altitude sickness, migraine attacks, poisoning/overdose, diabetic emergencies, smoke inhalation, breathing difficulties, allergy emergencies, seizures, chest pain, fainting, dehydration, near drowning, hyperthermia, injuries with trauma, burn victims, and other medical, general or civil emergencies. OxySure is also uniquely suited for homeland security applications (including emergency preparedness, mass casualty situations, etc.), civil emergencies, mining applications, and aviation applications.

The Innovation Expo is a collaboration between the USPTO and The Smithsonian designed to exhibit, showcase and celebrate American innovation and ingenuity. Candidates for the expo are selected from thousands of patent holders, including corporations, universities, the federal government and the inventor community that have commercialized innovation and new technological developments. Featured patented technologies will be breakthrough technologies and will have attained evident commercial success and influence and demonstrate significant contributions to both technological advancement and the standard of living in the United States. An example of an invention or product

that fits this criteria is one that has established a new market or significantly reshaped an existing market.

“We are honored and thrilled to be selected by the USPTO to participate in this historic event,” said Julian Ross, founder and CEO of OxySure. “We remain committed to innovation to save and improve lives, advance our common goals for our communities and society, and to maintain our global leadership,” he added.

About OxySure Systems, Inc.

OxySure Systems, Inc. (OXYS) is a medical technology company that focuses on the design, manufacture and distribution of specialty respiratory and medical solutions. The company pioneered a safe and easy to use solution to produce medically pure (USP) oxygen from inert powders. The company owns numerous issued patents and patents pending on this technology which makes the provision of emergency oxygen safer, more accessible and easier to use than traditional oxygen provision systems. OxySure's products improve access to emergency oxygen that affects the survival, recovery and safety of individuals in several areas of need: (1) Public and private places and settings where medical emergencies can occur; (2) Individuals at risk for cardiac, respiratory or general medical distress needing immediate help prior to emergency medical care arrival; and (3) Those requiring immediate protection and escape from exposure situations or oxygen-deficient situations in industrial, mining, military, or other "Immediately Dangerous to Life or Health" (IDLH) environments.

[www.OxySure.com](http://www.OxySure.com)

#### Forward-Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this release that are not historical facts, including, without limitation, statements that relate to the Company's expectations with regard to the future impact on the Company's results from new products in development, may be deemed to be forward-looking statements. Words such as "expects", "intends", "plans", "may", "could", "should", "anticipates", "likely", "believes" and words of similar import also identify forward-looking statements. These statements are subject to risks and uncertainties. Forward-looking statements are based on current facts and analyses and other information that are based on forecasts of future results, estimates of amounts not yet determined and assumptions of management. Readers are urged not to place undue reliance on the forward-looking statements, which speak only as of the date of this release. Except as may be required under applicable law, we assume no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release. Additional information on risks and other factors that may affect the business and financial results of OxySure Systems, Inc. can be found in the filings of OxySure Systems, Inc. with the U.S. Securities and Exchange Commission.

#### Investor Contacts:

Stonegate Securities, Inc.

[investors@oxysure.com](mailto:investors@oxysure.com)

214-987-4121 / 972-294-6461

<http://www.stonegateinc.com/>

Jon Cunningham

Redchip Companies, Inc.

800-733-2447, ext. 107

email us here

---

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2015 IPD Group, Inc. All Right Reserved.